Xu Ruihua

Research areas: Precision diagnosis and immunotherapy for digestive system tumors (colorectal cancer, gastric cancer, esophageal cancer), and clinical research on new cancer drugs.

Cutting-edge technologies: The team's achievements in early diagnosis and precision treatment of digestive system tumors have reached international leadership, with multiple research findings adopted by global cancer diagnosis and treatment standards and guidelines. The team's research on dual immunotherapy will be published on the cover of *Cancer Cell* in October 2025. The team promotes the "Chinese scholars + domestically developed new drugs" model, leading international and domestic multi-center clinical trials to facilitate the overseas approval and marketing of original Chinese drugs.

Specializes in treating: colorectal cancer, gastric cancer, esophageal cancer, and other digestive system tumors.

Academic Highlights and Core Values: Academician of the Chinese Academy of Engineering, Director and Dean of Sun Yat-sen University Cancer Center, and core expert of the National Key Laboratory for Prevention and Treatment of Malignant Tumors in South China. Received the National Innovation and Advancement Award and the Ho Leung Ho Lee Foundation Science and Technology Progress Award in 2023; the Annual Achievement Award from the Chinese Society of Clinical Oncology in 2024; and the First Prize of the Chinese Medical Science and Technology Award in 2025. Has international academic influence in the field of precision diagnosis and treatment and immunotherapy for digestive system tumors.